These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 32930616)

  • 1. Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
    Barroso-Sousa R; Tolaney SM
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):923-930. PubMed ID: 32930616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current usage of pembrolizumab in triple negative breast cancer (TNBC).
    O'Rourke H; Hart C; De Boer RH
    Expert Rev Anticancer Ther; 2024 May; 24(5):253-261. PubMed ID: 38594892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab for the treatment of breast cancer.
    Reddy SM; Carroll E; Nanda R
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):151-158. PubMed ID: 32067545
    [No Abstract]   [Full Text] [Related]  

  • 4. Pembrolizumab and atezolizumab in triple-negative breast cancer.
    Kwapisz D
    Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
    Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
    Front Immunol; 2021; 12():608292. PubMed ID: 34135884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
    Pusztai L; Denkert C; O'Shaughnessy J; Cortes J; Dent R; McArthur H; Kümmel S; Bergh J; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Zhu Y; Pan W; Tryfonidis K; Schmid P
    Ann Oncol; 2024 May; 35(5):429-436. PubMed ID: 38369015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.
    Mavratzas A; Seitz J; Smetanay K; Schneeweiss A; Jäger D; Fremd C
    Future Oncol; 2020 Jan; 16(3):4439-4453. PubMed ID: 31829043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
    N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Varma R; Wright M; Abraham J; Kruse M
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.
    Haiderali A; Huang M; Pan W; Akers KG; Maciel D; Frederickson AM
    Future Oncol; 2024; 20(22):1587-1600. PubMed ID: 38597713
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.
    Galsky MD; Mortazavi A; Milowsky MI; George S; Gupta S; Fleming MT; Dang LH; Geynisman DM; Walling R; Alter RS; Kassar M; Wang J; Gupta S; Davis N; Picus J; Philips G; Quinn DI; Haines GK; Hahn NM; Zhao Q; Yu M; Pal SK
    J Clin Oncol; 2020 Jun; 38(16):1797-1806. PubMed ID: 32271672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
    Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
    J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Mohamed A; Kruse M; Tran J
    Expert Rev Anticancer Ther; 2023; 23(10):1071-1084. PubMed ID: 37747062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab.
    Buisseret L; Bareche Y; Venet D; Girard E; Gombos A; Emonts P; Majjaj S; Rouas G; Serra M; Debien V; Agostinetto E; Garaud S; Willard-Gallo K; Larsimont D; Stagg J; Rothé F; Sotiriou C
    ESMO Open; 2024 May; 9(5):102964. PubMed ID: 38703428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab for the treatment of gastric cancer.
    Kamath SD; Kalyan A; Benson AB
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1177-1187. PubMed ID: 30280940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of immune checkpoint inhibition in triple negative breast cancer.
    Tarekegn K; Keskinkilic M; Kristoff TJ; Evans ST; Kalinsky K
    Expert Rev Anticancer Ther; 2023; 23(10):1095-1106. PubMed ID: 37771270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for the treatment of metastatic small cell lung cancer: Focus on pembrolizumab.
    Koulouris A; Mountzios G
    Expert Rev Clin Pharmacol; 2021 Jun; 14(6):651-659. PubMed ID: 33902379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of pembrolizumab based therapies in triple-negative breast cancer: A systematic review of clinical trials.
    Ali MA; Aiman W; Shah SS; Hussain M; Kashyap R
    Crit Rev Oncol Hematol; 2021 Jan; 157():103197. PubMed ID: 33309890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab for advanced cervical cancer: safety and efficacy.
    De Felice F; Giudice E; Bolomini G; Distefano MG; Scambia G; Fagotti A; Marchetti C
    Expert Rev Anticancer Ther; 2021 Feb; 21(2):221-228. PubMed ID: 33183120
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.